377220 — From Bio Co Balance Sheet
0.000.00%
- KR₩52bn
- KR₩65bn
- KR₩67bn
Annual balance sheet for From Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6,459 | 12,557 | 44,104 | 26,810 | 6,440 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4,395 | 4,627 | 4,454 | 3,561 | 3,034 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 15,553 | 30,975 | 71,717 | 53,560 | 37,653 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6,577 | 12,515 | 20,333 | 33,309 | 47,027 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 24,239 | 44,992 | 96,414 | 93,823 | 97,364 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,221 | 18,250 | 11,646 | 6,428 | 21,906 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 34,449 | 21,352 | 11,987 | 5,868 | 20,719 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | -10,210 | 23,640 | 84,427 | 87,955 | 76,645 |
Total Liabilities & Shareholders' Equity | 24,239 | 44,992 | 96,414 | 93,823 | 97,364 |
Total Common Shares Outstanding |